Mezaton 1% / 1 ml 10s solution for injection in ampoules

The instruction for medical use



of PHENYLEPHINE HYDROCHLORIDE medicine



the Trade name

the Phenylephine hydrochloride



the International unlicensed





name Fenilefrin Lekarstvennaya a form

Solution for injections of 1%



Structure

of 1 ml of solution contains

active agent - Phenylephrinum a hydrochloride of 0.01 g,

excipients: glycerin, water for injections.



Description

Transparent colourless liquid



Pharmacotherapeutic

Adreno-group and dopaminomimetik.

The ATX C01CA06 code



the Pharmacological



Pharmacokinetics Drug properties quickly comes to body tissues, for 95% contacts proteins of blood plasma. It is metabolized with participation of a monoaminooxidase in a liver and digestive tract (without participation catechol-au-methyltransferase). It is excreted mainly with urine. The effect at intravenous administration lasts 20 min., at introduction under skin of 40-50 minutes. Elimination half-life makes 2-3 hours.



The pharmacodynamics

the Phenylephine hydrochloride belongs to group of adrenomimetichesky substances of stimulators of a-adrenoceptors, affects heart b-adrenoceptors a little. Narrows arterioles and increases arterial blood pressure, practically does not influence the size of warm emission. Causes expansion of pupils (less for a long time, than atropine and without influence on accommodation), in an open angle glaucoma can reduce intraocular pressure. Is more resistant, than catecholamines, to action catechol-au-methyltransferase, than its more long-term effects speak.



Indications

- arterial hypotension

- shock states (in t. traumatic, toxic h)

- vascular insufficiency (in t. h against the background of overdose of vazodilatator)

- intranazalno vasomotorial and allergic rhinitis

- as a vasoconstrictor when carrying out local anesthesia

- as adrenaline substitute in solutions of local anesthetics for mydriasis.





The route of administration and doses

administer the Drug intravenously, subcutaneously, intramusculary, as drop/solution for eyes.

In an acute lowering of arterial pressure the drug is administered intravenously in doses of 0.1-0.3-0.5 ml of 1% of solution in 20 ml of 5% of-20% of solutions of glucose, or in the same volumes of isotonic solution of sodium of chloride. Introduction is carried out slowly, if necessary introduction is repeated. At a drop way enter 1 ml of 1% of solution of the Phenylephine hydrochloride into 250-500 ml of 5% of solution of glucose. Subcutaneously and intramusculary the adult enter 0.3-1 ml of 1% of solution in doses.

For mydriasis in a conjunctival sac dig in 1-2% of solution of drug on 2-3 drops. For the purpose of vasoconstriction of mucous membranes of a nasal cavity and reduction of expressiveness of inflammation, solutions dig in 0.25-0.5% or mucous membranes grease with these solutions. To local anesthetics (on 10 ml of solution of anesthetic) add 0.3-0.5 ml of 1% of solution of the Phenylephine hydrochloride.

The highest doses for adults: intravenously single 0.005 g, daily 0.025 g, subcutaneously and intramusculary single 0.01 g, daily 0.05 g.



Side effects

- arterial hypertension, pains in heart, fibrillation of ventricles of heart

- the dispepsichesky phenomena

- a headache, dizziness,

- sensation of fear, concern, weakness, pallor of face skin

- respiratory depression, a tremor, spasms

- at topical administration in ophthalmology eye pain, conjunctiva hyperaemia, allergic reaction a century









Contraindications

- arterial hypertension, atherosclerosis, tendency to vascular spasms, unstable stenocardia, dekompensirovanny heart failure, a myocardial infarction

- diabetes

- pregnancy

- bradycardia, disturbance of warm conductivity

- a prostatauxe

- a hyper thyroidism

- children's age up to 15 years.



Medicinal interactions

the Vasoconstrictive effect of the Phenylephine hydrochloride is weakened at joint action with aminosyn and other fenotiazinovy derivatives. At combined use with furasolidone the Phenylephine hydrochloride can cause hypertensive crisis, owing to fast release of noradrenaline.



Special instructions

during treatment it is necessary to control arterial blood pressure and the electrocardiogram.

With care appoint at advanced age, at an anesthesia (ftorotanovy), coronary heart disease, a hyperthyroidism, renal failures.

The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms

during therapy should not be engaged in the dangerous types of activity demanding speed of motor and mental reactions (including driving of the car).



Overdose

Symptoms: ventricular premature ventricular contraction, short paroxysms of ventricular tachycardia, heavy feeling in the head and extremities, substantial increase of arterial blood pressure.

Treatment: intravenous administration of alpha adrenoblockers of short action (phentolamine), beta blockers (at disturbances of a rhythm).



A form of release and packing

Solution for injections of 1%.

On 2 ml in ampoules, on 10 ampoules in a pack together with the instruction for use





Storage conditions

Store in the place protected from light at a temperature from 15 With up to 25 C.

To store out of children's reach!





3 years

not to apply a period of storage after the expiration date specified on packing.



Prescription status

According to the prescription





LLC Opytnyy zavod GNTsLS Producer.

Ukraine, Kharkiv, Vorobyov St., 8.